Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria [0.03%]
2022年KLCA-NCC标准在磁共振常规对比剂及肝胆特异性对比剂诊断肝细胞癌效能分析：与2018年KLCA-NCC标准比较
Ja Kyung Yoon,Sunyoung Lee,Jeong Ah Hwang et al.
Ja Kyung Yoon et al.
Background/aim: This study aimed to determine the diagnostic performance of 2022 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) imaging criteria compared with the 2018 KLCA-NCC for hepatocellular carcin...
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma [0.03%]
2022年KLCA-NCC韩国肝细胞癌管理实践指南
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice g...
A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab [0.03%]
纳武单抗联合伊匹单抗治疗阿特朱单抗和贝伐珠单抗治疗失败的肝细胞癌伴肺转移致病情接近完全缓解1例报告
Hyung Jun Kim,Sang Youn Hwang,Jung Woo Im et al.
Hyung Jun Kim et al.
Recently, the efficacy of immuno-oncologic agents for advanced hepatocellular carcinoma (HCC) has been proven in several trials. In particular, atezolizumab with bevacizumab (AteBeva), as a first-line therapy for advanced HCC, has shown tre...
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment [0.03%]
合并经导管动脉化疗栓塞治疗和放疗作为巨块型肝细胞癌一线治疗方案的替代疗法
Sujin Jin,Won-Mook Choi,Ju Hyun Shim et al.
Sujin Jin et al.
Background/aim: The Barcelona Clinic Liver Cancer (BCLC) guidelines recommend systemic therapy as the only first-line treatment for patients with BCLC stage C hepatocellular carcinoma (HCC) despite its heterogeneity of di...
Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab [0.03%]
射波刀联合阿特珠单抗和贝伐珠单抗治疗门脉瘤栓肝癌1例
Yong Tae Kim,Jina Kim,Jinsil Seong
Yong Tae Kim
Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While t...
Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study [0.03%]
超声在韩国国家肝细胞癌筛查项目中的应用现状——一项大规模多中心研究
Sun Hong Yoo,Soon Sun Kim,Sang Gyune Kim et al.
Sun Hong Yoo et al.
Background/aim: Abdominal ultrasonography (USG) is recommended as a surveillance test for high-risk groups for hepatocellular carcinoma (HCC). This study aimed to analyze the current status of the national cancer surveill...
Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report [0.03%]
肝癌并门静脉瘤栓侵犯的经导管动脉放射性粒子植入及阿特珠单抗和贝伐珠单抗联合治疗：1例报告
Min Kyung Park,Su Jong Yu
Min Kyung Park
Treatment options for advanced hepatocellular carcinoma (HCC) have been rapidly evolving. Herein, we describe a patient with advanced HCC and portal vein tumor thrombosis (PVTT) who responded decisively to a multidisciplinary approach. The ...
Complete response to local therapy for advanced hepatocellular carcinoma with lung metastasis: a case report [0.03%]
晚期肝细胞癌伴肺转移接受局部治疗后的完全反应一例报告
Daeun Kim,Seiyeon Park,Won Sohn et al.
Daeun Kim et al.
The concept of oligometastasis is widely accepted for various types of solid tumors; accordingly, better outcomes can be anticipated with aggressive local interventions. The treatment of advanced hepatocellular carcinoma (HCC) with extrahep...
Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria [0.03%]
索拉非尼联合放疗治疗晚期侵犯门静脉和肝静脉延伸至下腔静脉的肝细胞癌1例——mRECIST标准完全反应
Yuri Cho,Bo Hyun Kim,Tae Hyun Kim et al.
Yuri Cho et al.
The prognosis of patients with advanced hepatocellular carcinoma (HCC) with tumor thrombus extending to the inferior vena cava (IVC) is extremely poor. Herein, we present a rare case of advanced HCC that was treated with sorafenib and radio...